Royalty Pharma plc (RPRX) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..
Borrowing debt
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 380.00M USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 8.58B USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | 836.99M USD | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 19.82B USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $380.00M | $8.58B | (m) | $836.99M | $19.82B | (m) |
| 2026-03-31 | (m) | (m) | $380.00M | $8.58B | (m) | $608.29M | $19.82B | (m) |
| 2025-12-31 | (m) | (m) | $380.00M | $8.57B | (m) | $637.50M | $19.62B | (m) |
| 2025-09-30 | (m) | (m) | $380.00M | $8.57B | (m) | $955.04M | $19.35B | (m) |
| 2025-06-30 | (m) | (m) | $999.44M | $7.00B | (m) | $645.11M | $18.32B | (m) |
| 2025-03-31 | (m) | (m) | $998.61M | $6.62B | (m) | $1.10B | $17.61B | (m) |
| 2024-12-31 | (m) | (m) | $997.77M | $6.61B | (m) | $987.23M | $18.22B | (m) |
| 2024-09-30 | (m) | (m) | $996.94M | $6.61B | (m) | $998.55M | $18.04B | (m) |
| 2024-06-30 | (m) | (m) | $0.00 | $7.60B | (m) | $1.80B | $17.66B | (m) |
| 2024-03-31 | (m) | (m) | $0.00 | $6.14B | (m) | $872.00M | $16.13B | (m) |
| 2023-12-31 | (m) | (m) | $0.00 | $6.14B | (m) | $495.31M | $16.38B | (m) |
| 2023-09-30 | (m) | (m) | $0.00 | $6.13B | (m) | $941.75M | $15.86B | (m) |
| 2023-06-30 | (m) | (m) | $999.37M | $6.13B | (m) | $2.18B | $17.12B | (m) |
| 2023-03-31 | (m) | (m) | $998.44M | $6.12B | (m) | $1.98B | $17.07B | (m) |
| 2022-12-31 | (m) | (m) | $997.51M | $6.12B | (m) | $1.71B | $16.81B | (m) |
| 2022-09-30 | (m) | (m) | $996.58M | $6.11B | (m) | $1.40B | $17.67B | (m) |
| 2022-06-30 | (m) | (m) | $0.00 | $7.11B | (m) | $2.47B | $17.74B | (m) |
| 2022-03-31 | (m) | (m) | $0.00 | $7.10B | (m) | $1.86B | $17.38B | (m) |
| 2021-12-31 | (m) | (m) | $0.00 | $7.10B | (m) | $1.61B | $17.52B | (m) |
| 2021-09-30 | (m) | (m) | $0.00 | $7.09B | (m) | $1.87B | $17.73B | (m) |
| 2021-06-30 | (m) | (m) | $0.00 | $5.83B | (m) | $1.21B | $16.51B | (m) |
| 2021-03-31 | (m) | (m) | $0.00 | $5.82B | (m) | $778.07M | $15.91B | (m) |
| 2020-12-31 | (m) | (m) | $0.00 | $5.82B | (m) | $1.08B | $16.02B | (m) |
| 2020-09-30 | (m) | (m) | $0.00 | $5.81B | (m) | $1.60B | $15.99B | (m) |
| 2020-06-30 | (m) | (m) | $182.23M | $5.73B | (m) | $2.47B | $15.69B | (m) |
| 2019-12-31 | (m) | (m) | $281.98M | $5.96B | (m) | $283.68M | $12.45B | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |